Gossamer Bio, Inc.

Healthcare · Biotechnology · United States

Last price 10.38 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 63.49M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup comp...